TAIPEI (Taiwan News) — Taiwan’s Adimmune Corp. announced Monday that its enterovirus 71 vaccine has received regulatory approval in Macau, a move expected to support the company’s expansion into international markets.

The company said the region has faced repeated enterovirus outbreaks in recent years, including cluster infections in nurseries and kindergartens last year. Local health authorities have therefore prioritized prevention and vaccination, according to CNA.

Adimmune expects approval of EnVAX-A71 to encourage families in the Pearl River Delta — including Macau, Hong Kong, and the nearby Chinese city of Zhuhai — to vaccinate their children. The vaccine protects children aged 2 months to under 6 years against EV71, a type of enterovirus, according to Tungs’ Taichung MetroHarbor Hospital.

While the vaccine cannot prevent severe illness from other enterovirus types, most serious cases have historically been caused by EV71. Cathay General Hospital pediatrics director Shen Chung-min (沈仲敏) noted that vaccination can still prevent the majority of severe enterovirus infections and remains beneficial for children, according to Premium Parenting.

The company said gaps in enterovirus prevention across the region have created strong demand for vaccines that reduce infection and severe illness. Macau’s healthcare system could help maintain stable vaccination coverage once the vaccine is incorporated into the public health program, potentially positioning the city as a model for enterovirus prevention strategies.

Adimmune has also submitted enterovirus vaccine applications in Vietnam and Thailand and plans to expand further across Southeast Asia while accumulating long-term clinical data to support future regulatory submissions. Its initial focus is on high-risk countries including Vietnam, Thailand, Malaysia, and Indonesia, where enterovirus infections have circulated widely for more than two decades.